CRISPR-Cas Systems Guide RNA

A component of CRISPR-Cas SYSTEMS. Cas endodeoxyribonucleases assemble with a guide RNA complex, a hybrid of CRISPR RNA (crRNA) and transactivating crRNA (tracrRNA) molecules, to form an active complex that cleaves DNA. crRNA and tracrRNA can be synthetically fused into a single RNA molecule, namely single guide RNA. Synthetic sgRNA is used with CRISPR-Cas SYSTEMS for targeted GENE EDITING.

Also Known As:

RNA, Guide, CRISPR-Cas Systems; Guide RNA, CRISPR; Guide RNA, CRISPR Cas Systems; Guide RNA, Single; CRISPR Guide RNA; CRISPR-Cas Systems sgRNA (Single Guide RNA); Guide RNA (CRISPR-Cas Systems); Guide RNA, CRISPR-Cas Systems; RNA, CRISPR Guide; RNA, Guide (CRISPR-Cas Systems); RNA, Single Guide; RNA, Single-Guide; Single Guide RNA; Single-Guide RNA; Transactivating crRNA; crRNA; crRNA, Transactivating; sgRNA (CRISPR-Cas Systems); sgRNA (Single-Guide RNA); tracrRNA

Networked: 112 relevant articles (2 outcomes, 12 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleic Acids: 11752
  - RNA: 69704
    - Untranslated RNA: 2850
      - Small Untranslated RNA: 566
        CRISPR-Cas Systems Guide RNA: 112

Experts

1.	Kang, Chunsheng: 3 articles (11/2020 - 10/2019)
2.	Yi, Kaikai: 3 articles (11/2020 - 10/2019)
3.	Wang, Jiang: 2 articles (01/2022 - 12/2020)
4.	Doudna, Jennifer A: 2 articles (09/2021 - 10/2017)
5.	Knott, Gavin J: 2 articles (09/2021 - 10/2017)
6.	Alzahrani, Badr: 2 articles (07/2021 - 01/2021)
7.	Farhana, Aisha: 2 articles (07/2021 - 01/2021)
8.	Mok, Pooi Ling: 2 articles (07/2021 - 01/2021)
9.	Tong, Jiabei: 2 articles (07/2021 - 01/2021)
10.	Jiang, Wenyan: 2 articles (01/2021 - 02/2016)

Related Diseases

1.	Mitochondrial Diseases (Mitochondrial Disease) 09/09/2023 - "We presume that imported crRNA allow reconstituting the active crRNA/Cas12a system in human mitochondria, which can contribute to the development of effective strategies for mitochondrial gene editing and potential future treatment of mitochondrial diseases." 01/01/2021 - "Inhibition of Orai1 with single guide RNA (sgOrai1) or an inhibitor (BTP2) not only suppressed Drp1 activity and calmodulin-binding catalytic subunit A (CnA) and phosphorylated-extracellular signal-regulated kinase (p-ERK1/2) expression but also alleviated mitochondrial dysfunction and cardiomyocyte hypertrophy caused by HG. In addition, the CnA inhibitor cyclosporin A and p-ERK1/2 inhibitor U0126 improved HG-induced cardiomyocyte hypertrophy by promoting and inhibiting phosphorylation of Drp1 at S637 and S616, respectively. "
2.	Hearing Loss (Hearing Impairment) 02/01/2022 - "Overall, this CRISPR-based NAT technology provides a sensitive and fast new approach for the detection of hereditary deafness and provides a crRNA optimization strategy for single-nucleotide polymorphism detection, which could be helpful for the clinical diagnosis of SLC26A4 mutation-related hereditary hearing loss."
3.	Hypertrophy 01/01/2021 - "Inhibition of Orai1 with single guide RNA (sgOrai1) or an inhibitor (BTP2) not only suppressed Drp1 activity and calmodulin-binding catalytic subunit A (CnA) and phosphorylated-extracellular signal-regulated kinase (p-ERK1/2) expression but also alleviated mitochondrial dysfunction and cardiomyocyte hypertrophy caused by HG. In addition, the CnA inhibitor cyclosporin A and p-ERK1/2 inhibitor U0126 improved HG-induced cardiomyocyte hypertrophy by promoting and inhibiting phosphorylation of Drp1 at S637 and S616, respectively. "
4.	Deafness (Deaf Mutism) 02/01/2022 - "Overall, this CRISPR-based NAT technology provides a sensitive and fast new approach for the detection of hereditary deafness and provides a crRNA optimization strategy for single-nucleotide polymorphism detection, which could be helpful for the clinical diagnosis of SLC26A4 mutation-related hereditary hearing loss."
5.	Neoplasms (Cancer) 11/28/2023 - "Induction of CRISPR-dCas9-KRAB expression through the PSA promoter may help feedback inhibition of cellular PSA gene expression via single guide RNA (sgRNA), thereby monitoring and suppressing the malignant state of tumor cells. " 01/01/2023 - "Cas9-expressing tumor cells are transduced with a library of pooled single-guide RNA (sgRNA)-expressing lentiviruses that target all human genes to obtain a cell population where each cell is knocked out for a single gene. " 01/01/2023 - "In Vitro CRISPR-Cas12a-Based Detection of Cancer-Associated TP53 Hotspot Mutations Beyond the crRNA Seed Region." 01/01/2020 - "In addition, we used subcutaneous xenograft tumor growth assays to find that the weight and volume of tumors in the SiHa-16E6CR1 group knocked down by the CRISPR/Cas13a system were significantly lower than those in the SiHa-VECTOR group lacking crRNA. " 01/01/2020 - "To identify epigenetic regulators of tumor immunity, we constructed an epigenetic-focused single guide RNA library and performed an in vivo CRISPR screen in a Kras G12D/Trp53 -/- LUAD model. "

Related Drugs and Biologics

1.	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)
2.	Cyclosporine (Ciclosporin)
3.	Calmodulin (Calcium-Dependent Activator Protein)
4.	U 0126 (UO 126)
5.	N-acetyltalosaminuronic acid (NAT)
6.	Ribonucleoproteins
7.	RNA (Ribonucleic Acid)
8.	Proteins (Proteins, Gene)
9.	CRISPR-Associated Protein 9
10.	DNA (Deoxyribonucleic Acid)

Related Therapies and Procedures

1.	Transplantation
2.	Therapeutics
3.	Injections
4.	Immunotherapy
5.	Fecal Microbiota Transplantation